← Russell 3000 cross-section

MIR Mirion Technologies, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$3.7bn
Revenue TTM
$1.0bn
Net income TTM
$24m
Free cash flow
$134m
Composite score
45.2
Sector rank
#1276

Valuation

P / E
149.5
EV / EBITDA
18.0
EV / sales
3.6
FCF yield
3.65%
Earnings yield vs 10-yr
-4.06pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
2.4%
EBITDA margin
20.0%
ROE
1.3%
ROIC
2.9%
Revenue growth
15.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The following key factors affecting our performance have included, and we anticipate they will continue to affect our future results: • Nuclear end market trends —Growth and operating results in our Nuclear & Safety segment are impacted by: • Our products are installed at the vast majority of addressable active nuclear power reactors globally, creating full lifecycle sales opportunities. For consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to noncontrolling interests is reported as “Income (loss) attributable to noncontrolling interests” in the unaudited Condensed Consolidated Statements of Operations. …Mirion Technologies, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →